Danish devices association urges authorities to deter reuse firm
This article was originally published in Clinica
Denmark's state serum institute (SSI) has denied suggestions that it has in any way approved the practices of German medical devices reprocessing company Vanguard. This statement comes despite the publication of a report by SSI in which it claims that the resterilisation of single-use devices is defensible "in certain cases". In reply to a letter from Medicoidustrien, the medical devices industry association, SSI said that it did not even have the authority to approve such procedures.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.